flurbiprofen has been researched along with Cancer of Prostate in 15 studies
Flurbiprofen: An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.
flurbiprofen : A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain.
| Excerpt | Relevance | Reference |
|---|---|---|
| "(R)-flurbiprofen has been generally well tolerated at high doses in clinical trials." | 2.44 | Drug evaluation: (R)-flurbiprofen--an enantiomer of flurbiprofen for the treatment of Alzheimer's disease. ( Geerts, H, 2007) |
| "Prostate cancer is still one of the serious causes of mortality and morbidity in men." | 1.56 | Synthesis, Anticancer Activity on Prostate Cancer Cell Lines and Molecular Modeling Studies of Flurbiprofen-Thioether Derivatives as Potential Target of MetAP (Type II). ( Bayer, B; Bekçi, H; Cumaoğlu, A; Küçükgüzel, ŞG; Uba, AI; Yelekçi, K; Yılmaz, Ö, 2020) |
| "Expression of p75(NTR) is lost as prostate cancer progresses and is minimal in several metastatic prostate cancer cell lines." | 1.36 | NSAID inhibition of prostate cancer cell migration is mediated by Nag-1 Induction via the p38 MAPK-p75(NTR) pathway. ( Djakiew, D; Wynne, S, 2010) |
| "We used TRAMP C1 murine prostate cancer cells to examine potential mechanisms through which RFB could regulate psca." | 1.33 | Gene expression profiling in R-flurbiprofen-treated prostate cancer: R-Flurbiprofen regulates prostate stem cell antigen through activation of AKT kinase. ( Bashkirova, S; Chen, CS; Lilly, MB; Reiter, R; Wechter, W; Zemskova, M, 2006) |
| "The development of prostate cancer has been linked to high level of dietary fat intake." | 1.30 | Up-regulation of cyclooxygenase-2 by product-prostaglandin E2. ( Hughes-Fulford, M; Tjandrawinata, RR, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 9 (60.00) | 29.6817 |
| 2010's | 2 (13.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Lan, K | 1 |
| Yang, WB | 1 |
| Zhang, XW | 1 |
| Bai, WJ | 1 |
| Li, Q | 1 |
| Xu, T | 1 |
| Yılmaz, Ö | 1 |
| Bayer, B | 1 |
| Bekçi, H | 1 |
| Uba, AI | 1 |
| Cumaoğlu, A | 1 |
| Yelekçi, K | 1 |
| Küçükgüzel, ŞG | 1 |
| Wynne, S | 1 |
| Djakiew, D | 3 |
| Sato, N | 1 |
| Masai, M | 1 |
| Hughes-Fulford, M | 4 |
| Li, CF | 1 |
| Boonyaratanakornkit, J | 1 |
| Sayyah, S | 1 |
| Zemskova, M | 1 |
| Wechter, W | 1 |
| Bashkirova, S | 1 |
| Chen, CS | 1 |
| Reiter, R | 1 |
| Lilly, MB | 1 |
| Geerts, H | 1 |
| Quann, EJ | 2 |
| Khwaja, F | 2 |
| Zavitz, KH | 1 |
| Tjandrawinata, RR | 2 |
| Dahiya, R | 1 |
| Lokeshwar, BL | 1 |
| Houston-Clark, HL | 1 |
| Selzer, MG | 1 |
| Block, NL | 1 |
| Golub, LM | 1 |
| Wechter, WJ | 1 |
| Leipold, DD | 1 |
| Murray, ED | 1 |
| Quiggle, D | 1 |
| McCracken, JD | 1 |
| Barrios, RS | 1 |
| Greenberg, NM | 1 |
| Chen, Y | 1 |
| Keegan, P | 1 |
| Loughman, BE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison Study of a Low-Fat Diet Supplemented With Fish Oil and a Standard Western Diet in Individuals With Prostate Cancer[NCT00798876] | 56 participants (Actual) | Interventional | 2001-12-18 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for flurbiprofen and Cancer of Prostate
| Article | Year |
|---|---|
[The trends in new drugs for the prostate cancer].
Topics: Adenoviridae; Androgen Antagonists; Antibodies, Monoclonal; Antineoplastic Agents; Aziridines; Cance | 2002 |
Drug evaluation: (R)-flurbiprofen--an enantiomer of flurbiprofen for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials, Phase I as Top | 2007 |
1 trial available for flurbiprofen and Cancer of Prostate
| Article | Year |
|---|---|
[Application of flurbiprofen axetil in pain management associated during transrectal ultrasound-guided prostate biopsy].
Topics: Anesthetics, Local; Biopsy; Flurbiprofen; Humans; Lidocaine; Male; Nerve Block; Pain Management; Pro | 2017 |
12 other studies available for flurbiprofen and Cancer of Prostate
| Article | Year |
|---|---|
Synthesis, Anticancer Activity on Prostate Cancer Cell Lines and Molecular Modeling Studies of Flurbiprofen-Thioether Derivatives as Potential Target of MetAP (Type II).
Topics: Aminopeptidases; Antineoplastic Agents; Cell Line, Tumor; Drug Delivery Systems; Flurbiprofen; Human | 2020 |
NSAID inhibition of prostate cancer cell migration is mediated by Nag-1 Induction via the p38 MAPK-p75(NTR) pathway.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cell Line, Tumor; Cell Movement; Flurbiprofen; Growth Diffe | 2010 |
Arachidonic acid activates phosphatidylinositol 3-kinase signaling and induces gene expression in prostate cancer.
Topics: Arachidonic Acid; Cell Growth Processes; Chromones; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; E | 2006 |
Gene expression profiling in R-flurbiprofen-treated prostate cancer: R-Flurbiprofen regulates prostate stem cell antigen through activation of AKT kinase.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Dr | 2006 |
The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cell Survival; Dose-Response Relationship, Drug; Flurbiprof | 2007 |
The p38 MAPK pathway mediates aryl propionic acid induced messenger rna stability of p75 NTR in prostate cancer cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Eukaryotic Initiation Factor-4E; Flurbiprofen; Humans; Ibup | 2007 |
Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells.
Topics: 16,16-Dimethylprostaglandin E2; Anti-Ulcer Agents; Breast Neoplasms; Cell Count; Cell Division; Cycl | 1997 |
Up-regulation of cyclooxygenase-2 by product-prostaglandin E2.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Carcinoma; Cell Transformation, Neoplastic; Cyclooxygenase | 1997 |
Potential application of a chemically modified non-antimicrobial tetracycline (CMT-3) against metastatic prostate cancer.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Cell Division; D | 1998 |
E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse.
Topics: Adenocarcinoma; Animals; Body Weight; Dietary Fats; Disease Models, Animal; Disease Progression; Flu | 2000 |
Prostaglandin E2 and the protein kinase A pathway mediate arachidonic acid induction of c-fos in human prostate cancer cells.
Topics: Arachidonic Acid; Cyclic AMP-Dependent Protein Kinases; Dinoprostone; Flurbiprofen; Gene Expression; | 2000 |
Early clinical trials of chemopreventive and biologic agents: Designs, populations, and endpoints.
Topics: Anticarcinogenic Agents; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trial | 2001 |